

**REMARKS**

The Office Action and the Advisory Action have been carefully reviewed. No claim is allowed. Claims 17, 19, 29, 30 and 34-39 presently appear in this application and define patentable subject matter warranting their allowance.

Reconsideration and allowance are hereby respectfully solicited.

Claims 17-19, 29, 30 and 34-39 have been rejected under 35 U.S.C. §112, first paragraph, as failing to comply with the written description requirement. This rejection is respectfully traversed.

Claims 19 and 34 are now amended to recite adult T lymphoid leukemia (ATL) disclosed on page 2, line 22 of the present specification for which there is evidence of synergistic efficacy, as discussed with the examiner after receipt of the Advisory Action. Attached hereto is a copy of a publication by some of the inventors of the instant application, Bazarbachi et al., *Blood* 93(1):278-283 (1999), published after the priority filing date of July 31, 1998, but before the U.S. filing date of July 30, 1999. This publication demonstrates the synergistic effect of arsenic trioxide and interferon- $\alpha$  in inducing cell cycle arrest and apoptosis of adult T-cell leukemia (ATL).

Reconsideration and withdrawal of the rejection are therefore respectfully requested.

Appln. No. 09/744,605  
Amd. dated October 23, 2006  
Reply to Office Action of July 31, 2006

In view of the above, the claims comply with 35 U.S.C.  
§112 and define patentable subject matter warranting their  
allowance. Favorable consideration and early allowance are  
earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By /ACY/  
Allen C. Yun  
Registration No. 37,971

ACY:pp  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528

G:\BN\S\Ser1\Roken1\Pto\2006-10-23amendment.doc